{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T16:10:59Z","timestamp":1778861459286,"version":"3.51.4"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["3332022111"],"award-info":[{"award-number":["3332022111"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","award":["2022-PUMCH-C-060"],"award-info":[{"award-number":["2022-PUMCH-C-060"]}],"id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","award":["2022-PUMCH-B-028"],"award-info":[{"award-number":["2022-PUMCH-B-028"]}],"id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272380"],"award-info":[{"award-number":["82272380"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072318"],"award-info":[{"award-number":["82072318"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFC2301002"],"award-info":[{"award-number":["2021YFC2301002"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jgar.2025.05.011","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T11:15:34Z","timestamp":1747307734000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Clinical imipenem non-susceptible Klebsiella pneumoniae isolates from China: Epidemiology, molecular characterization and in vitro activity of imipenem\/relebactam"],"prefix":"10.1016","volume":"44","author":[{"given":"Peiyao","family":"Jia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5174-955X","authenticated-orcid":false,"given":"Pengcheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaobing","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ge","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingchun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiwen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2025.05.011_bib0001","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jgar.2025.05.011_bib0002","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1007\/s10096-019-03673-1","article-title":"Resistance reported from China antimicrobial surveillance network (CHINET) in 2018","volume":"38","author":"Hu","year":"2019","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2025.05.011_bib0003","article-title":"Molecular epidemiology and antimicrobial resistance profiles of Klebsiella pneumoniae isolates from hospitalized patients in different regions of China","volume":"14","author":"Li","year":"2024","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.jgar.2025.05.011_bib0004","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.2147\/IDR.S410657","article-title":"Epidemiological and antimicrobial resistant patterns, and molecular mechanisms of carbapenem-resistant Klebsiella pneumoniae infections in ICU patients","volume":"16","author":"Lu","year":"2023","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jgar.2025.05.011_bib0005","article-title":"Clinical characteristics of respiratory tract infection caused by Klebsiella pneumoniae in immunocompromised patients: a retrospective cohort study","volume":"13","author":"Liu","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.jgar.2025.05.011_bib0006","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/cid\/ciz530","article-title":"RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem\/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections","volume":"70","author":"Motsch","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2025.05.011_bib0007","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/phar.2378","article-title":"Imipenem-cilastatin-relebactam: a novel \u03b2-lactam-\u03b2-lactamase inhibitor combination for the treatment of multidrug-resistant gram-negative infections","volume":"40","author":"Smith","year":"2020","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jgar.2025.05.011_bib0008","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.cmi.2022.01.025","article-title":"In vitro activity of imipenem-relebactam against KPC-producing Klebsiella pneumoniae resistant to ceftazidime-avibactam and\/or meropenem-vaborbactam","volume":"28","author":"Lombardo","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2025.05.011_bib0009","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2147\/IDR.S203572","article-title":"Susceptibilities of gram-negative bacilli from hospital- and community-acquired intra-abdominal and urinary tract infections: a 2016-2017 update of the Chinese SMART study","volume":"12","author":"Zhang","year":"2019","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jgar.2025.05.011_bib0010","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2147\/IDR.S343673","article-title":"The genomic characterization of KPC-producing Klebsiella pneumoniae from the ICU of a teaching hospital in Shanghai, China","volume":"15","author":"Du","year":"2022","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jgar.2025.05.011_bib0011","unstructured":"EUCAST. Breakpoint tables for interpretation of MICs and zone diameters. Version 11.0, 2021."},{"key":"10.1016\/j.jgar.2025.05.011_bib0012","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jgar.2020.10.023","article-title":"Clinical characteristics and outcomes of patients with multidrug-resistant gram-negative bacterial infections treated with ceftazidime\/avibactam","volume":"23","author":"Kuang","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2025.05.011_bib0013","article-title":"The rapid emergence of ceftazidime-avibactam resistance mediated by KPC variants in carbapenem-resistant Klebsiella pneumoniae in Zhejiang province, China","volume":"11","author":"Liu","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.jgar.2025.05.011_bib0014","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1089\/mdr.2019.0299","article-title":"Analysis of the drug resistance of carbapenem-resistant Klebsiella pneumoniae in the China Antimicrobial Resistance Surveillance Trial Program, 2007-2018","volume":"26","author":"Gao","year":"2020","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.jgar.2025.05.011_bib0015","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s44280-023-00009-9","article-title":"Current status and trends of antimicrobial resistance among clinical isolates in China: a retrospective study of CHINET from 2018 to 2022","volume":"1","author":"Yang","year":"2023","journal-title":"One Health Adv"},{"key":"10.1016\/j.jgar.2025.05.011_bib0016","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.jinf.2022.03.010","article-title":"Risk factors for infection and mortality caused by carbapenem-resistant Klebsiella pneumoniae: a large multicentre case-control and cohort study","volume":"84","author":"Lou","year":"2022","journal-title":"J Infect"},{"key":"10.1016\/j.jgar.2025.05.011_bib0017","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/s41579-019-0315-1","article-title":"Population genomics of Klebsiella pneumoniae","volume":"18","author":"Wyres","year":"2020","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.jgar.2025.05.011_bib0018","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/jac\/dkq431","article-title":"ST11, the dominant clone of KPC-producing Klebsiella pneumoniae in China","volume":"66","author":"Qi","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2025.05.011_bib0019","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2021.724212","article-title":"An outbreak of carbapenem-resistant Klebsiella pneumoniae of K57 capsular serotype in an emergency intensive care unit of a teaching hospital in China","volume":"9","author":"Shao","year":"2021","journal-title":"Front Public Health"},{"key":"10.1016\/j.jgar.2025.05.011_bib0020","article-title":"Detection of CRISPR\u2012Cas and type I R-M systems in Klebsiella pneumoniae of human and animal origins and their relationship to antibiotic resistance and virulence","volume":"13","author":"Li","year":"2025","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.jgar.2025.05.011_bib0021","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.3390\/microorganisms11081948","article-title":"Correlation of CRISPR\/Cas and antimicrobial resistance in Klebsiella pneumoniae clinical isolates recovered from patients in Egypt compared to global strains","volume":"11","author":"Alkompoz","year":"2023","journal-title":"Microorganisms"},{"key":"10.1016\/j.jgar.2025.05.011_bib0022","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1017\/ice.2020.68","article-title":"Enhanced survival of ST-11 carbapenem-resistant Klebsiella pneumoniae in the intensive care unit","volume":"41","author":"Liu","year":"2020","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.jgar.2025.05.011_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2023.115945","article-title":"Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam activities against multidrug-resistant Enterobacterales from United States Medical Centers (2018-2022)","volume":"106","author":"Sader","year":"2023","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2025.05.011_bib0024","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.3390\/antibiotics11111621","article-title":"Epidemiology and in vitro activity of ceftazidime\/avibactam, meropenem\/vaborbactam and imipenem\/relebactam against KPC-producing K. pneumoniae collected from bacteremic patients, 2018 to 2020","volume":"11","author":"Bovo","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.jgar.2025.05.011_bib0025","doi-asserted-by":"crossref","first-page":"S196","DOI":"10.1093\/cid\/ciy660","article-title":"Phenotypic and genotypic characterization of carbapenem-resistant Enterobacteriaceae: data from a longitudinal large-scale CRE study in China (2012-2016)","volume":"67","author":"Wang","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2025.05.011_bib0026","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1080\/22221751.2020.1799721","article-title":"Prevalence, risk factors and molecular epidemiology of carbapenem-resistant Klebsiella pneumoniae in patients from Zhejiang, China, 2008-2018","volume":"9","author":"Hu","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.jgar.2025.05.011_bib0027","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13756-019-0674-4","article-title":"Epidemiological characteristics of carbapenem-resistant Enterobacteriaceae collected from 17 hospitals in Nanjing district of China","volume":"9","author":"Zhou","year":"2020","journal-title":"Antimicrob Resist Infect Control"},{"key":"10.1016\/j.jgar.2025.05.011_bib0028","doi-asserted-by":"crossref","DOI":"10.1099\/jmm.0.001325","article-title":"Molecular characterization of carbapenem-resistant Enterobacteriaceae and emergence of tigecycline non-susceptible strains in the Henan province in China: a multicentrer study","volume":"70","author":"Yan","year":"2021","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.jgar.2025.05.011_bib0029","doi-asserted-by":"crossref","first-page":"S427","DOI":"10.1093\/cid\/ciaa1519","article-title":"In vitro activity of imipenem\/relebactam against Enterobacteriaceae isolates obtained from intra-abdominal, respiratory tract, and urinary tract infections in China: study for monitoring antimicrobial resistance trends (SMART), 2015-2018","volume":"71","author":"Yang","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2025.05.011_bib0030","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12866-023-02864-3","article-title":"Relebactam restores susceptibility of resistant Pseudomonas aeruginosa and Enterobacterales and enhances imipenem activity against chromosomal AmpC-producing species: analysis of global SMART 2018-2020","volume":"23","author":"Hilbert","year":"2023","journal-title":"BMC Microbiol"},{"key":"10.1016\/j.jgar.2025.05.011_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2022.106660","article-title":"Susceptibility of OXA-48-producing Enterobacterales to imipenem\/relebactam, meropenem\/vaborbactam and ceftazidime\/avibactam","volume":"60","author":"Bonnin","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2025.05.011_bib0032","doi-asserted-by":"crossref","first-page":"5029","DOI":"10.1128\/AAC.00830-15","article-title":"Activity of imipenem with relebactam against gram-negative pathogens from New York City","volume":"59","author":"Lapuebla","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.05.011_bib0033","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1089\/mdr.2018.0065","article-title":"Effect of porins and bla(KPC) expression on activity of imipenem with relebactam in Klebsiella pneumoniae: can antibiotic combinations overcome resistance?","volume":"24","author":"Balabanian","year":"2018","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.jgar.2025.05.011_bib0034","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/jac\/dkac100","article-title":"Dynamic evolution of imipenem\/relebactam resistance in a KPC-producing Klebsiella pneumoniae from a single patient during ceftazidime\/avibactam-based treatments","volume":"77","author":"Gaibani","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2025.05.011_bib0035","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02165-19","article-title":"Activity of imipenem-relebactam against a large collection of Pseudomonas aeruginosa clinical isolates and isogenic \u03b2-lactam-resistant mutants","volume":"64","author":"Fraile-Ribot","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.05.011_bib0036","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1093\/jac\/dkae203","article-title":"Penicillin-binding protein 3 sequence variations reduce susceptibility of Pseudomonas aeruginosa to \u03b2-lactams but inhibit cell division","volume":"79","author":"Glen","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2025.05.011_bib0037","article-title":"Genomic epidemiology and characterization of carbapenem-resistant Klebsiella pneumoniae in ICU inpatients in Henan province, China: a multicenter cross-sectional study","volume":"11","author":"Wang","year":"2023","journal-title":"Microbiol Spectr"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716525001146?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716525001146?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:25:02Z","timestamp":1778858702000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716525001146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":37,"alternative-id":["S2213716525001146"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2025.05.011","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical imipenem non-susceptible Klebsiella pneumoniae isolates from China: Epidemiology, molecular characterization and in vitro activity of imipenem\/relebactam","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2025.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Merck & Co., Inc., Rahway, NJ, USA and its affiliates and The Author(s).  Published by Elsevier Ltd. on behalf of International Society for Antimicrobial Chemotherapy","name":"copyright","label":"Copyright"}]}}